[A long-term survivor with stage IV gastric cancer due to postoperative weekly paclitaxel and 5'-DFUR combination
Tomoki Fukasawa1, Teruaki Shoji, Hideki Gotoh
1Dept. of Surgery, Kambara Municipal Hospital.
Abstract:
The patient was a 63-year-old woman who presented with upper abdominal discomfort. Type 3 gastric cancer in the midgastric region was diagnosed, and the patient underwent surgery. Because peritoneal metastasis and periaortic lymph node metastasis were confirmed, paraaortic lymph node metastasis, total gastrectomy and D 1 lymph node dissection were performed. Surgical and pathological findings were pType 3, pT 3(SE), sN 3, pP 1, sH 0, CY 1, Stage IV, and Cur C. After surgery, she was treated with five regimens of MTX/5-FU, TS-1 or DOC, but because progressive disease was confirmed, weekly paclitaxel and 5'-DFUR combination therapy was initiated as salvage therapy. Five months after the start of combination therapy, complete response was achieved, and combination therapy was continued for 19 more months. Since no recurrence was observed, therapy was terminated. No severe adverse reactions were observed. The patient has been recurrence-free for 25 months and remains alive as of 68 months after surgery. The present therapy may thus be effective in the treatment of previously treated Cur C advanced gastric cancer.
Related Concept Videos
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

